DE19729810C2 - Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung - Google Patents
Mittel zur Sepsistherapie, seine Herstellung und seine VerwendungInfo
- Publication number
- DE19729810C2 DE19729810C2 DE19729810A DE19729810A DE19729810C2 DE 19729810 C2 DE19729810 C2 DE 19729810C2 DE 19729810 A DE19729810 A DE 19729810A DE 19729810 A DE19729810 A DE 19729810A DE 19729810 C2 DE19729810 C2 DE 19729810C2
- Authority
- DE
- Germany
- Prior art keywords
- lbp
- sepsis
- therapy
- lps
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 23
- 238000002560 therapeutic procedure Methods 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims abstract description 44
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims abstract description 43
- 241001529936 Murinae Species 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 3
- 239000002158 endotoxin Substances 0.000 claims description 20
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 20
- 230000001960 triggered effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 241000701447 unidentified baculovirus Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000192125 Firmicutes Species 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 claims 2
- 101001023403 Rattus norvegicus Lipopolysaccharide-binding protein Proteins 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000013223 septicemia Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 231100000699 Bacterial toxin Toxicity 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000688 bacterial toxin Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101150072740 Lbp gene Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19729810A DE19729810C2 (de) | 1997-07-11 | 1997-07-11 | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung |
| PCT/DE1998/000964 WO1999002178A1 (de) | 1997-07-11 | 1998-04-04 | Mittel zur sepsistherapie, seine herstellung und seine verwendung |
| DK98928139T DK0999849T3 (da) | 1997-07-11 | 1998-04-04 | Anvendelse af LBP til sepsisbehandling |
| JP2000501768A JP2001509488A (ja) | 1997-07-11 | 1998-04-04 | 敗血症治療薬、その製造及び使用 |
| DE59805440T DE59805440D1 (de) | 1997-07-11 | 1998-04-04 | Verwendung von lbp zur sepsistherapie |
| PT98928139T PT999849E (pt) | 1997-07-11 | 1998-04-04 | Utilizacao de lbp no tratamento da septicemia |
| AT98928139T ATE223227T1 (de) | 1997-07-11 | 1998-04-04 | Verwendung von lbp zur sepsistherapie |
| EP98928139A EP0999849B1 (de) | 1997-07-11 | 1998-04-04 | Verwendung von lbp zur sepsistherapie |
| ES98928139T ES2183376T3 (es) | 1997-07-11 | 1998-04-04 | Uso de lbp para el tratamiento de la septicemia. |
| US09/484,121 US6949512B1 (en) | 1997-07-11 | 2000-01-13 | Therapeutic agent for the treatment of septicaemia its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19729810A DE19729810C2 (de) | 1997-07-11 | 1997-07-11 | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19729810A1 DE19729810A1 (de) | 1999-01-14 |
| DE19729810C2 true DE19729810C2 (de) | 2000-01-13 |
Family
ID=7835437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19729810A Expired - Fee Related DE19729810C2 (de) | 1997-07-11 | 1997-07-11 | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung |
| DE59805440T Expired - Lifetime DE59805440D1 (de) | 1997-07-11 | 1998-04-04 | Verwendung von lbp zur sepsistherapie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59805440T Expired - Lifetime DE59805440D1 (de) | 1997-07-11 | 1998-04-04 | Verwendung von lbp zur sepsistherapie |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6949512B1 (enExample) |
| EP (1) | EP0999849B1 (enExample) |
| JP (1) | JP2001509488A (enExample) |
| AT (1) | ATE223227T1 (enExample) |
| DE (2) | DE19729810C2 (enExample) |
| DK (1) | DK0999849T3 (enExample) |
| ES (1) | ES2183376T3 (enExample) |
| PT (1) | PT999849E (enExample) |
| WO (1) | WO1999002178A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2108372A1 (en) * | 2008-04-09 | 2009-10-14 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Novel antimicrobial peptides |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025476A1 (en) * | 1993-04-30 | 1994-11-10 | Incyte Pharmaceuticals, Inc. | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
| WO1995005393A2 (en) * | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995008560A1 (en) * | 1993-09-24 | 1995-03-30 | Centocor, Inc. | Novel peptides useful for inhibiting binding of lipopolysaccharides (lps) by lipopolysaccharide binding protein (lbp) |
| US5837810A (en) * | 1994-03-15 | 1998-11-17 | The Scripps Research Institute | Polypeptides of lipopolysaccharide binding protein |
| US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
-
1997
- 1997-07-11 DE DE19729810A patent/DE19729810C2/de not_active Expired - Fee Related
-
1998
- 1998-04-04 PT PT98928139T patent/PT999849E/pt unknown
- 1998-04-04 WO PCT/DE1998/000964 patent/WO1999002178A1/de not_active Ceased
- 1998-04-04 AT AT98928139T patent/ATE223227T1/de not_active IP Right Cessation
- 1998-04-04 DE DE59805440T patent/DE59805440D1/de not_active Expired - Lifetime
- 1998-04-04 ES ES98928139T patent/ES2183376T3/es not_active Expired - Lifetime
- 1998-04-04 DK DK98928139T patent/DK0999849T3/da active
- 1998-04-04 EP EP98928139A patent/EP0999849B1/de not_active Expired - Lifetime
- 1998-04-04 JP JP2000501768A patent/JP2001509488A/ja active Pending
-
2000
- 2000-01-13 US US09/484,121 patent/US6949512B1/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025476A1 (en) * | 1993-04-30 | 1994-11-10 | Incyte Pharmaceuticals, Inc. | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
| WO1995005393A2 (en) * | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| DE59805440D1 (de) | 2002-10-10 |
| WO1999002178A1 (de) | 1999-01-21 |
| JP2001509488A (ja) | 2001-07-24 |
| US6949512B1 (en) | 2005-09-27 |
| DE19729810A1 (de) | 1999-01-14 |
| DK0999849T3 (da) | 2003-01-06 |
| EP0999849B1 (de) | 2002-09-04 |
| PT999849E (pt) | 2003-01-31 |
| EP0999849A1 (de) | 2000-05-17 |
| ATE223227T1 (de) | 2002-09-15 |
| ES2183376T3 (es) | 2003-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433562T2 (de) | Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel | |
| DE69830582T2 (de) | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind | |
| DE69905368T2 (de) | Oxydiertes thymosin beta 4 | |
| DE69519454T2 (de) | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen | |
| DE3650150T2 (de) | Modulator der anabolischen Aktivität und seine Verwendungen. | |
| EP1224940B2 (de) | Flüssige Interferon-Beta Formulierungen | |
| DE3853918T2 (de) | Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. | |
| DE60107815T2 (de) | Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren | |
| DE3879685T2 (de) | Potenzierung der erythropoiesis. | |
| DE3686794T2 (de) | Reinigung des natuerlichen kolonie-stimulierenden faktors-1. | |
| DE69713485T2 (de) | Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie | |
| DE202007018618U1 (de) | G-CSF-Flüssigformulierung | |
| WO2000029567A1 (de) | Rekombinante glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung | |
| DE3586826T2 (de) | Cdna-klone, kodierend fuer peptide mit der wirksamkeit eines menschlichen granulocyte-, makrophage- und eosinophilzellenwachstumsfaktors. | |
| EP1644028B1 (de) | Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen | |
| DE69034076T2 (de) | Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie | |
| DE3855747T2 (de) | Biologische materialien, deren herstellung und verwendung in der therapie | |
| DE69322654T2 (de) | Verfahren zur herstellung von kristallen des wachstumshormones und die so erhaltenen kristalle | |
| DE69509631T2 (de) | Zusammensetzungen und methoden zur stimulation der produktion von blutplättchen mittels nicht gebundenem mpl-rezeptor | |
| DE19729810C2 (de) | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung | |
| DE69527145T2 (de) | Verfahren zur behandlung von blutungsstorungen | |
| WO2002004487A2 (de) | Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen | |
| DE3436638C2 (de) | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen | |
| DE69737986T2 (de) | Epimorphin antagonist und herstellungsverfahren dafür | |
| EP2694090B1 (de) | Arzneimittel enthaltend rekombinante mistellektine zur behandlung des malignen melanoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |